HCV Care Pathway in Ile-de-France

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02893046

Acronym

ParcoursVHC

Enrollment

1000

Registered

2016-09-08

Start date

2016-09-30

Completion date

2019-09-30

Last updated

2016-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C Virus

Keywords

care pathway, hospital- private network, early consultation

Brief summary

The main objective of this research is to evaluate a care pathway adapted to different category populations at risk of being infected with the hepatitis C virus in order to improve both the diagnosis turnaround times and the access to treatment. The aim is to allow a quick and effective access to diagnosis and treatment of HCV by strengthening the city hospital networks, access to early consultations and coordination of medical social actors.

Detailed description

The current estimation of infected persons with chronic hepatitis C in France is over 200 ,000. It appears that prevention, screening, care management, medical and social care of patients can be significantly improved especially among the most vulnerable populations. Indeed, these new HCV infections are mediated by drug-using people, prisoners, migrants, men who have sex with men (MSM) and who are supported too late and without real access to treatment.

Interventions

OTHERNo intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years old and more * Positive Hepatitis C virus * Patient having expressed a non-objection to participate in this research

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame
Number of patients effectively cared divided by number of patients eligible to care.	Year 3

Secondary

Measure	Time frame
Number of patients cared in the HCV care pathway in Ile-de-France	Year 3
Number of patients effectively treated divided by number of patients eligible to DAA treatment.	Year 3
Delay between HCV diagnosis and early consultation	Year 3

Countries

France

Contacts

Primary ContactStéphanie DOMINGUEZ, MD

stephanie.dominguez@aphp.fr(0)1 49 81 25 26

Backup ContactAntoine BACHELARD, MD

antoine.bachelard2@aphp.fr(0)1 49 81 25 26

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026